Clene(us:CLNN)
5.00
+5.93%
Updated on 2024-12-25
Open:4.72
Close:5.00
High:5.05
Low:4.50
Pre Close:4.72
Volume:42433.00
Amount:207071.80
Turnover:0.53%
Shares:7.98M
MarketCap:39.90M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 45 | 337688 | 0.26% | 3 | 12 | 17 |
| 2024-03-31 | 52 | 7293292 | 5.68% | 7 | 8 | 17 |
| 2023-12-31 | 56 | 11633714 | 9.06% | 10 | 10 | 18 |
| 2023-09-30 | 54 | 24632828 | 19.18% | 5 | 15 | 16 |
| 2023-06-30 | 53 | 32289324 | 25.15% | 21 | 7 | 7 |
| 2023-03-31 | 40 | 3034133 | 3.89% | 6 | 8 | 15 |
| 2022-12-31 | 45 | 3081718 | 4.12% | 9 | 8 | 18 |
| 2022-09-30 | 53 | 4328041 | 6.81% | 11 | 8 | 28 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 2619703 | 2.04% | 1315 | 0.05% |
| 2024-03-31 | Geode Capital Management, Llc | 946532 | 0.74% | 334653 | 54.69% |
| 2024-03-31 | Lunt Capital Management, Inc. | 512863 | 0.40% | 0 | |
| 2024-03-31 | Scoggin Management Lp | 500000 | 0.39% | -250000 | -33.33% |
| 2024-03-31 | Alyeska Investment Group, L.P. | 474130 | 0.37% | -1212760 | -71.89% |
| 2024-03-31 | Morgan Stanley | 338635 | 0.26% | 0 | |
| 2024-03-31 | Laird Norton Wetherby Trust Company, Llc | 268581 | 0.21% | 0 | |
| 2024-03-31 | Citadel Advisors Llc | 235241 | 0.18% | -46098 | -16.39% |
| 2024-03-31 | Blackrock Inc. | 180009 | 0.14% | -284209 | -61.22% |
| 2024-03-31 | Northern Trust Corp | 169225 | 0.13% | 3726 | 2.25% |
About
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Address:6550 South Millrock Drive,Suite G50
Website:http://www.clene.com
Market Movers